Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Priority
PNG
media_image1.png
20
338
media_image1.png
Greyscale
, is acknowledged.
Status of Claims
Claims 1-16 and 22-25 are currently pending in the application. Claims 17-21 were canceled.
Receipt is acknowledged of amendment / response filed on January 26, 2026 and that has been entered.
Information Disclosure Statement
Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 01/26/2026, which has been entered in the file.
Response to Election/Restriction
In response to the restriction requirement, Applicants have elected Group I, which includes claims 1-16, drawn to a compound of formula (I) or a pharmaceutically acceptable salt thereof and the elected species as set forth and found to a compound, such as,
PNG
media_image2.png
144
200
media_image2.png
Greyscale
, without traverse, is acknowledged.
Claims 22-25 are withdrawn from further consideration pursuant to 37 C.F.R. 1.142 (b) as being drawn to a non-elected subject matters and therefore, the requirement for restriction is still deemed proper made it final.
Applicants preserve their right to file a divisional on the non-elected subject matter.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-16 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Lehmann et al (2009). Applicant claims anti-viral compound of formula (I), pharmaceutical compositions and their method of uses thereof. Lehmann et al also disclose several identical compounds and compositions, which anticipate the instantly claimed inventions [
PNG
media_image3.png
112
146
media_image3.png
Greyscale
, where X1-X5 are C, R5 = phenyl; Y = C=O; R3 = H; R1 = C2 alkylene R1a, with R1a = NR6R7; where R6 and R7 are C1 alkyl; L1 is absent; R2 = phenyl with R8 (halo), Figure 1, page 4657, a copy is provided with this Office action].
Claims 1-16 are also rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Lu et al (2014). Applicant claims anti-viral compound of formula (I), pharmaceutical compositions and their method of uses thereof. Lu et al also disclose several identical compounds and compositions, which anticipate the instantly claimed inventions [
PNG
media_image4.png
90
150
media_image4.png
Greyscale
, the amines at bottom of page 353, where L = meta substituted phenyl, and the amine is the N-CH(CH3)Ph, amine like compound 23, pages 353-355, a copy is provided with this Office action].
Objections
The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code (The specification contains a hyperlink at [007]). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
Telephone Inquiry
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 7:30 AM - 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks, Ph.D. can be reached at (571) 270-7682.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.
/GOLAM M SHAMEEM/Primary Examiner, Art Unit 1621
Prosecution Insights